Table 3.
Descriptive statistics, odds ratios (OR), and corresponding p-values in the prospective study estimated using age-adjusted generalized linear models with the logit link function. CI—confidence interval.
| Non-IFG † | IFG ‡ | Odds Ratio § | |
|---|---|---|---|
| Δ % waist circumference (cm) | 99.86 ± 0.73 | 103.11 ± 1.07 | OR = 1.06 (CI 1.01–1.1) (p < 0.01) |
| Δ % hip circumference (cm) | 98.26 ± 0.74 | 100.64 ± 0.91 | OR = 1.05 (CI 1.0–1.0) (p = 0.03) |
| Δ % muscle mass (%) | 102.77 ± 1.30 | 102.79 ± 1.50 | OR = 0.99 (CI 0.9–1.05) (p = 0.98) |
| Δ % HOMA-IR | 125.65 ± 8.42 | 142.80 ± 8.52 | OR = 1.004 (CI 1.0–1.008) (p = 0.05) |
| Δ % visceral fat (%) | 85.61 ± 4.14 | 97.53 ± 5.70 | OR = 1.01 (CI 0.9–1.02) (p = 0.09) |
| Δ % subcutaneous fat (%) | 110.51 ± 2.62 | 108.26 ± 3.92 | OR = 0.99 (CI 0.9–1.01) (p = 0.62) |
| Δ % VAT/SAT ratio | 82.34 ± 5.62 | 100.77 ± 9.21 | OR = 1.01 (CI 0.9–1.01) (p = 0.09) |
† Non-IFG subjects who remained non-IFG at the follow-up visit; mean ± standard error; ‡ IFG subjects who were diagnosed with IFG at the follow-up visit; mean ± standard error; § age adjusted. VAT/SAT ratio—visceral adipose tissue/subcutaneous adipose tissue ratio; HOMA-IR—homeostatic model assessment estimated insulin resistance.